Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 5Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Solid Tumors 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

sacituzumab govitecan 1bintrafusp alfa protein, human 1avelumab 1Tomography, X-Ray Computed 1Nivolumab 1Ipilimumab 1Gemcitabine 1Electrocardiography 1Echocardiography 1DOXO-EMCH 1(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Solid Tumors × sacituzumab govitecan × Clear all
NCT04319198 2025-09-30

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Gilead Sciences

Phase 4 Completed
25 enrolled 15 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡